Ernexa shareholders approve reverse stock split, share increase to 150M, and written consent

Ernexa Therapeutics Inc.

Elected all five director nominees: James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner, William Wexler.
Approved amendment to increase authorized common stock from 100M to 150M shares.
Approved reverse stock split at Board's discretion within 1-for-10 to 1-for-15 ratio.
Approved stockholder action by written consent, removing meeting-only requirement.
Ratified Grant Thornton as auditor for 2025 and approved potential issuance >20% under March 31 securities purchase agreement.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.